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Abstract
Gene therapy of genetic diseases requires persistent and position-independent expression of a therapeutic transgene.
Transcriptional enhancers binding chromatin-remodeling and modifying complexes may play a role in shielding transgenes
from repressive chromatin effects. We tested the activity of the HS2 enhancer of the GATA1 gene in protecting the
expression of a b-globin minigene delivered by a lentiviral vector in hematopoietic stem/progenitor cells. Gene expression
from proviruses carrying GATA1-HS2 in both LTRs was persistent and resistant to silencing at most integration sites in the in
vivo progeny of human hematopoietic progenitors and murine long-term repopulating stem cells. The GATA1-HS2-modified
vector allowed correction of murine b-thalassemia at low copy number without inducing clonal selection of erythroblastic
progenitors. Chromatin immunoprecipitation studies showed that GATA1 and the CBP acetyltransferase bind to GATA1-HS2,
significantly increasing CBP-specific histone acetylations at the LTRs and b-globin promoter. Recruitment of CBP by the LTRs
thus establishes an open chromatin domain encompassing the entire provirus, and increases the therapeutic efficacy of b-
globin gene transfer by reducing expression variegation and epigenetic silencing.
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Introduction
b-thalassemias are a group of autosomal recessive disorders
characterized by reduced or absent synthesis of hemoglobin b-
chains. Allogeneic bone marrow (BM) transplantation from
HLA-matched related donors provides a definitive cure for this
disease [1]. Gene therapy, i.e., transplantation of autologous,
genetically corrected hematopoietic stem cells (HSCs), is a
potential alternative for patients lacking a compatible donor.
Gene therapy of b-thalassemia requires efficient transfer and
appropriately regulated expression of a b-globin transgene.
Lentiviral vectors (LV) carrying a human b-globin gene under
the control of its minimal promoter and elements of the ß-globin
locus-control region (LCR) transduce repopulating HSCs and
allow long-term correction of the murine and human b-
thalassemia phenotype in pre-clinical models [2,3,4,5,6]. Limited
therapeutic efficacy has been recently observed in one patient
treated with transduced CD34
+ human hematopoietic stem/
progenitor cells (HPCs) [7].
A significant limitation of existing b-globin vectors is variegation
and epigenetic silencing of transgene expression, which the activity
of the b-globin LCR is not sufficient to overcome [8]. Several
attempts have been undertaken to reduce chromatin-mediated
silencing, such as the introduction of insulators or scaffold/matrix-
attachment regions (S/MARs) in the vector backbone. Insertion
of a 1.2-kb insulator derived from a chicken a-globin DNase
hypersensitive site (cHS4) in the viral long terminal repeats (LTRs)
led to complete correction of the thalassemic phenotype in the
erythroblastic progeny of transduced human HPCs in vitro and
in vivo [4,9]. Insertion of the cHS4 in the LTRs has, however,
detrimental effects on the vector titer, which is partially overcome
by reducing the insulator size [10,11]. A 573-bp insulator isolated
from the sea urchin arylsulfatase locus (ArsI) was reported to
protect LV from silencing by maintaining an active chromatin
structure in an orientation-dependent manner, though not in all
cell types or differentiation stages [12,13]. Another sea urchin
chromatin insulator, sns5, was shown to protect a gamma-
retroviral vector from the negative influence of chromatin in a
mouse erythroid cell line [14]. Addition of S/MARs from the
human b-interferon or immunoglobulin heavy chain loci, alone or
in combination with insulators and enhancers, reduces silencing
and provides position-independent transgene expression in
hematopoietic cell lines and primary cells [15,16,17]. More
recently, a ubiquitously acting chromatin opening element
(UCOE) from the human HNRPA2B1-CBX3 locus has been
successfully used to minimize the influences of neighboring
chromatin on single-copy transgene expression in hematopoietic
cells [18,19].
An alternative strategy to protect an integrated expression
cassette from the effect of the surrounding chromatin is the use of
transcriptional enhancers, such as the metallothionein or a-globin
HS40 enhancer or the DNase hypersensitive site II (HS2) of the
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cultured cells [20,21,22,23]. In the class of erythroid-specific
enhancers, the GATA1-HS2, is a 200-bp element from the gene
encoding GATA1 [24], a transcriptional activator that operates as
a general switching factor for erythroid development [25]. GATA1
binds to the consensus sequence WGATAR within globin LCRs
and regulatory regions of erythroid-specific genes and interacts
with CBP, a histone acetyltransferase (HAT) that stimulates
GATA1 transcriptional activity [26] by inducing an open
chromatin configuration. CBP can directly acetylate GATA1
and, consequently, facilitates GATA1 chromatin occupancy
[27,28]. The HS2 element contains a high affinity, palindromic
GATA1 binding element that mediates positive autoregulation of
GATA1 expression [29,30] and binds the transcription factors CP2
[31] and BCL11A [32].
In this study, we tested the ability of GATA1-HS2 in
counteracting repressive chromatin effects in the context of
LV-delivered transgenes. The element was inserted into the
LTRs of a LV expressing a GFP gene under the control of the
silencing-prone cytomegalo v i r u s( C M V )p r o m o t e ro rab-globin
minigene under the control of a reduced-size LCR. The activity
of these vectors was tested in the progeny of transduced,
repopulating murine HSCs and human CD34
+ cells. We show
that the GATA1-HS2 is able to increase the probability of long-
term transgene expression, and to rescue the thalassemic
phenotype at low copy number in a murine model of the disease.
Chromatin immunoprecipitation (ChIP) studies showed that
GATA1 and CBP bind GATA1-HS2-containing LTRs and
induce hyperacetylation at specific histone residues throughout
t h ep r o v i r u s .T h e s er e s u l t ss h o wt h a ta ne f f e c t i v ea p p r o a c ht o
shield integrated transgenes from negative chromosomal position
effects is represented by the inclusion in LV LTRs of sequences
co-targeted by transcription factors and chromatin modifying
enzymes.
Results
A strategy to achieve persistent and position-
independent transgene expression in erythroblastic cells
We previously reported that the GATA1-HS2 element cloned in
transcriptionally active viral LTR drives erythroid-restricted
transgene expression in both MLV- and HIV-derived vectors
[33,34]. To test whether GATA1-HS2 may positively influence the
long-term transgene expression in erythroblastic cells, a previously
described [35] LV expressing GFP from the CMV promoter
(CMV-GFP, Figure 1A) was modified by cloning the 200-bp HS2
element in the 39 LTR, to obtain the G-CMV-GFP vector
(Figure 1B). The CMV promoter was chosen because of its high
susceptibility to silencing in vitro and in vivo [18]. The activity of the
CMV-GFP and G-CMV-GFP vectors was comparatively ana-
lyzed following transduction of murine HSCs and human cord
blood-derived, CD34
+ cells.
The GATA1-HS2 element protects the CMV promoter
from silencing in the erythroid progeny of murine HSCs
BM cells from CD45.1 C57BL/6 (C57BL/6-Ly-5.1) mice were
transduced with either the CMV-GFP or the G-CMV-GFP
vector and transplanted in lethally-irradiated CD45.2 co-isogenic
mice ((C57BL/6; n=9 and n=8, respectively). Transduction
efficiency, calculated as percentage of GFP
+ colony forming
cells (CFCs) in methylcellulose assay, averaged 75% for both
vectors (data not shown). Engraftment of donor cells, as
proportion of CD45.1
+ to total CD45
+ cells, ranged from 88 to
99% at 12 months after transplantation. BM from recipient
animals was analyzed for GFP expression in the erythroid
(Ter119
+) and non-erythroid (Ter119
2) progeny of transduced,
long-term repopulating HSCs. The proportion of Ter119
bright
cells was comparable in both groups (3462% and 3662%, for
CMV-GFP and G-CMV-GFP, respectively). GFP
+ cells were
detected at a significantly higher proportion in the Ter119
+
compartment of mice transplanted with G-CMV-GFP-trans-
duced HSCs, compared to mice transplanted with CMV-GFP-
transduced HSCs (5664% vs.2 8 68%, P,0.05, Figure 2A and
Figure S1A). The mean fluorescence intensity (MFI) of
Ter119
+/GFP
+ cells was also significantly higher in mice
transplanted with G-CMV-GFP-transduced cells (208625 vs.
96610, P,0.001, Figure 2A and Figure S1B). Conversely, the
proportion of GFP
+ cells and the MFI in the Ter119
2,m y e l o i d
and lymphoid compartments were comparable in the two groups
(29611% vs.3 2 65%: MFI: 372689 vs. 248623, Figure 2A).
The average vector copy number (VCN) in total BM cells,
analyzed by qPCR, was comparable in both groups (3.560.9 for
CMV-GFP vs.3 . 0 60.6 for G-CMV-GFP, P.0.1).
T oa n a l y z eg e n ee x p r e s s i o ni nt h ec l o n a lp r o g e n yo fl o n g - t e r m
HSCs, BM from primary transplanted animals (3 different
donors for each vector; Table S1) was transplanted in secondary
CD45.2 C57BL/6 recipients (n=8 per group, Table S1). A total
of 66 12-day colonies derived from spleen colony-forming unit
(CFU-S) cells were isolated and analyzed by PCR for the
presence of the provirus, and by cytofluorimetry for Ter119 and
GFP expression. The proportion of Ter119
bright cells was
comparable in both groups (data not shown). We observed a
.2-fold increase in the percentage of GFP
+ colonies carrying the
G-CMV-GFP vector compared to those carrying the CMV-GFP
vector (85% vs 40%; P,0.001, Figure 2B). The average VCN
detected by qPCR analysis was 1.4 and 1.8 for G-CMV-GFP and
CMV-GFP colonies, respectively (not shown). These data
indicate that the HS2 element significantly increases the
probability of transgene expression in the clonal erythroid
progeny of murine repopulating HSCs by reducing stable and/
or variegating position effect.
The GATA1-HS2 element maintains high level of
transgene expression in the erythroid progeny of human
HPCs in vitro and in vivo
We then tested the activity of CMV-GFP and G-CMV-GFP
vectors in human cord blood-derived CD34
+ cells. To analyze
transgene expression at clonal level, CMV-GFP- and G-CMV-
GFP-transduced CD34
+ cells were cultured in methylcellulose for
14 days, and single colonies were scored for GFP expression by
fluorescence microscopy inspection, and analyzed for the presence
of vector sequences by PCR. The vast majority (90%) of cells from
BFU-Es (erythroid burst-forming units) carrying the G-CMV-GFP
vector expressed the transgene compared to a significantly lower
proportion (63%) of those harboring the CMV-GFP vector
(P,0.005, Figure 3A), while no significant difference was
observed in the proportion of GFP
+ cells from CFU-GM
(granulocyte-macrophage colony-forming units) between the two
groups (75% vs. 68%, P.0.1, Figure 3B).
Transduced HPCs were then assayed in vivo after transplanta-
tion in sub-lethally irradiated NOD-SCID mice (n=5 and n=4
for the CMV-GFP and G-CMV-GFP vector). Transduction
efficiency ranged from 70 to 80% for both vectors. Eight to 11
weeks after transplantation, the engraftment of SCID-repopulating
cells (SRCs) ranged from 8 to 28%, as determined by the
proportion of human CD45
+ cells in the mouse BM. Staining
with antibodies against lineage markers (CD19, CD13, and
CD34) showed the presence of human lymphoid, myeloid, and
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tion of SRCs in both mouse groups (data not shown). Since human
erythroid differentiation occurs at low level in NOD-SCID
chimeras, we tested GFP expression in the erythroblastic progeny
of transduced SRCs ex vivo, in clonal cultures preferentially
supporting the growth of human progenitors. BFU-E colonies
were scored for both GFP expression and the presence of proviral
vectors. Overall, 33 out of 40 (83%) of the G-CMV-GFP-
transduced colonies expressed the transgene, compared to 33 out
of 53 (62%) in the case of CMV-GFP (P,0.05, Figure 3C). The
percentage of transduced CFU-GM colonies expressing the
transgene was comparable for the two vectors (77% and 75%
for CMV-GFP and G-CMV-GFP, respectively; Figure 3D).
These data show that that GATA1-HS2 partially protects a CMV-
driven transgene from silencing in the erythroid progeny of human
HPCs and SRCs.
The GATA1-HS2 element improves correction of the
murine b-thalassemia phenotype by low copy number of
a b-globin vector
We previously showed that the GLOBE LV, expressing a
human b-globin gene under the control of the b-globin promoter
and a reduced-size LCR (Figure 1C) is able to correct the murine
b-thalassemia phenotype by providing a selective advantage to
genetically corrected erythroblasts [5]. We therefore tested the
effect of introducing a copy of GATA1-HS2 in both LTRs of the
GLOBE vector (G-GLOBE, Figure 1D) on the expression of
the b-globin gene in a thalassemic mouse model. We used
heterozygous C57BL/6-Hbb
th3 knock-out mice (th3/+) [36],
which show a pathophysiology comparable to that of patients
with severe ß-thalassemia intermedia, that is chronic anemia,
anomalies in RBC size and shape, and ineffective erythropoiesis.
We transplanted 16 lethally-irradiated CD45.2, th3/+ mice with
Figure 1. Structure of CMV-GFP, G-CMV-GFP, GLOBE, G-GLOBE and PGK-GFP lentiviral vectors. (A–B) Schematic map of the CMV-GFP
and G-CMV-GFP vectors in their proviral form. In both vectors, the CMV promoter drives the expression of a GFP transgene. In the CMV-GFP vector,
the GATA1-HS2 enhancer was inserted into the self-inactivated LTRs (sin-18 LTRs) carrying 400 bp deletion in HIV U3 region (G sin-18 LTR). The rev-
responsive element (RRE), the splice donor site (SD), the splicing acceptor site (SA), the central polypurine tract (cPPT), the woodchuck post-
regulatory element (WPRE) are shown. (C) Schematic representation of the b-globin expressing G-GLOBE. The sin-18 LTR, RRE, SD, SA, cPPT, the
human b-globin gene, the 2265/+50 b-globin promoter (bp) and the human LCR Dnase I hypersensitive sites HS2 and HS3 are shown. (D) Schematic
representation of the b-globin expressing G-GLOBE vector. The GATA1-HS2 element was inserted into the self-inactivated LTRs (G sin 218 LTR). (E)
Structure of the PGK-GFP lentiviral vector. A GFP transgene is under the control of the human phospoglycerate kinase promoter (PGK).
doi:10.1371/journal.pone.0027955.g001
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either GLOBE or G-GLOBE (n=8 per group). Control mice
were transplanted with either wild-type cells (WT control, n=9) or
mock-transduced thalassemic cells (th3/+ control, n=8). Donor
chimerism was .90% at 9–12 months after transplantation in all
mice. The extent of phenotypic correction was similar in mice
transplanted with G-GLOBE and GLOBE-transduced BM: Hb
level, ineffective erythropoiesis (evaluated as percentage of
Ter119
+ cells in BM), hematocrit, RBC and reticulocyte counts
were equally improved compared to th3/+ controls (Figure 4A,
4B and Figure S2). Likewise, expression of human b-globin, as
analyzed by FACS analysis and HPLC, was comparable in the
two groups (Table S2). However, the average VCN in the
G-GLOBE-transduced, Ter119
+ cells was significantly lower than
in GLOBE-transduced erythroblasts (1.0260.36 vs. 1.7360.40,
P,0.05), while no difference was observed in the Ter119
2,
myeloid population between the two groups (0.7060.20 vs.
0.8360.30) (Figure 4C). No significant difference in the VCN
of Ter119
+ vs. Ter119
2 cells was observed in th3/+ mice
transplanted with HSCs transduced with a GFP-expressing vector
(0.8160.34 vs. 0.7860.32; P.0.1, Figure 1E and Figure 4C).
These results indicate that G-GLOBE is able to correct the murine
thalassemia at an average VCN of 1 without inducing selection of
erythroblasts harboring a higher number of proviruses, as
observed for the GLOBE vector.
The GATA1-HS2 element prevents silencing of a b-globin
transgene in the progeny of long-term repopulating
HSCs
To test the effect of GATA1-HS2 on b-globin transgene
expression in the clonal progeny of long-term repopulating HSCs,
BM cells harboring 0.3–1 GLOBE and 0.2–1 G-GLOBE average
vector copies per cell were harvested from primary transplanted
mice (4 donors per group) 12 months after transplantation and
injected in wild-type secondary recipients. We mapped 2 to 15
different predominant proviral integration sites in the total BM of
mice in the GLOBE group and 3 to 15 in mice in the G-GLOBE
group, as analyzed by LM-PCR and sequencing (Table S1).
Individual colonies from 12-day secondary CFU-S were isolated
from recipient mice and analyzed for the presence of the provirus
and for b-globin expression. qPCR analysis revealed that all
transduced colonies harbored a single proviral copy. Human b-
globin synthesis, detected by FACS analysis, was observed in
erythroblasts from 14 out of 24 G-GLOBE-containing splenic
colonies (58%), compared to 10 out of 40 GLOBE-containing
colonies (25%), indicating that GATA1-HS2 significantly increases
(P,0.005) the probability of transgene expression in the progeny
of long-term HSCs (Figure 5A). Interestingly, this effect was not
apparent in primary colonies from 12-day CFU-S: 10 out of 12
(83%) colonies harboring GLOBE and 15 out of 17 (88%) colonies
harboring G-GLOBE expressed human b-globin (P.0.1)
(Figure 5B). The average VCN was 1.6 for GLOBE-transduced
and 1.4 for G-GLOBE-transduced primary colonies.
Proviral integration sites in secondary CFU-S-derived colonies
were individually sequenced and mapped by LM-PCR. 5 out of 11
GLOBE and 10 out of 12 G-GLOBE integrations were associated
to transgene expression, while the remaining proviruses were
always silent (Table S3 and S4), showing that a G-GLOBE
provirus is less dependent on its genomic position than a GLOBE
provirus for transgene expression (45% vs. 83% of active
proviruses, Figure 5C). Indeed, some integrations (3 G-GLOBE
and 2 GLOBE), independently identified in different colonies,
were variably active (Table S3 and S4), indicating that position
effect variegation does occur in the progeny of long-term
repopulating HSCs. The number of these events was too small
to establish whether variegation is reduced by the presence of
GATA1-HS2 in the LTRs.
The integration pattern of the G-GLOBE vector is not
biased by the presence of the GATA1-HS2 element in the
LTRs
We previously showed that the introduction of the MLV
enhancer in the HIV LTR causes subtle changes in the integration
pattern of LV [37]. To test whether the presence of the GATA1-
HS2 element could bias LV integration, we analyzed the
integration site distribution of the CMV-GFP and G-CMV-GFP
vectors in the genome of human CD34
+ HPCs. A total of 438
CMV-GFP and 305 G-CMV-GFP integration sites were mapped
by LM-PCR, annotated as TSS-proximal, intragenic and
intergenic, and their relative distribution compared to that of
9,974 random control sequences (Figure S3A). Both vectors
integrate preferentially into genes (71.2% and 69.5% for CMV-
GFP and G-CMV-GFP, respectively, compared to 36.1% in the
control sequences, Figure S3A) with no preference for TSSs
(Figure S3B). To correlate vector integration with gene activity,
we determined the gene expression profile of CD34
+ cells at the
time of transduction by Affymetrix microarray analysis [6], and
analyzed the expression level of the genes targeted by the vectors.
As expected [38], both LV targeted preferentially active genes
compared to random controls (Figure S4). Finally, we correlated
vector integration sites and epigenetic modifications obtained from
previously published ChIP-sequencing data sets [39]. The 61-kb
regions flanking CMV-GFP and G-CMV-GFP integration sites
were equally enriched in PolII binding sites and transcription-
associated H3K4me1, H3K36me3, H4K20me1, H3K9me1, and
H3K27me1 histone modifications compared to random sequenc-
es, with no differences between CMV-GFP and G-CMV-GFP
(Figure S5). Similarly, H3K4me3, H3K9me3 and H3K27me3
modifications and binding of the H2A.Z histone variant were
under-represented around both LV integrations (Figure S5). The
presence of GATA1-HS2 in the LTR has therefore no apparent
influence on the selection of integration sites of the LV.
Figure 2. Analysis of transgene expression in the progeny of murine HSCs transduced with CMV-GFP and G-CMV-GFP. (A)
Representative FACS analysis of the BM sub-populations of mice transplanted with CMV-GFP-(mice #6 and #7) and G-CMV-GFP-(mice #14 and #15)
transduced cells and sacrificed 12 months after BMT. The cells were stained with an antibody that recognizes the erythroid-specific marker Ter119.
The presence of GATA1-HS2 into the LTRs (G-CMV-GFP vector) is able to sustain transgene expression in the Ter119
+ BM erythroid compartment. (B)
Single erytroid CFU-S were collected from the spleens of secondary recipients 12 days after transplantation with CMV-GFP and G CMV-GFP-containing
BM cells (7 and 9 mice, respectively). Donor BM cells are derived from primary transplanted mice which have received CMV-GFP- and G-CMV-GFP-
transduced BM cells (3 different donors for each vector). Vector-containing clones carrying a comparable number of proviral copies were analyzed by
FACS for transgene expression. The percentages of GFP
+ (light grey) and GFP
2(dark grey) vector-positive CFU-S are represented(LV
+). Transgene
expression was observed in 40% of CMV-GFP-containing CFU-S, whereas the presence of GATA1-HS2 element into the LTRs was able to sustain GFP
expression in 85% of G CMV-GFP-transduced CFU-S. The difference in the proportion of transgene expressing CFU-S between the two groups was
statistically significant (P,0.001; Fisher exact test).
doi:10.1371/journal.pone.0027955.g002
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GATA1 regulates all known erythroid-specific genes, often
through the association with the CBP histone acetyltransferase
[40]. To investigate whether GATA1 binds to the HS2-containing
LTRs and recruits CBP, ChIP experiments were carried out in
GATA1-expressing HEL cells transduced with either GLOBE or
G-GLOBE LV, using antibodies against GATA1 and CBP. PCR
primer pairs were used to amplify sequences corresponding to
the 59 LTR by qPCR analysis (Figures 6A). As expected,
GATA1 was highly enriched at GATA1-HS2-containing LTRs
(Figures 6B). Accordingly, CBP showed occupancy above
Figure 3. GATA1-HS2 is able to sustain transgene expression in the erythroid compartment differentiating from human HPCs. (A–B)
BFU-E and CFU-GM derived from CMV-GFP- and G-CMV-GFP-transduced CD34
+ cells were scored by PCR for vector integration and for GFP
expression under fluorescence microscopy. The percentages of GFP
+ (dark grey) and GFP
2 (light grey) colonies among the vector-containing BFU-E
are represented (for each sample set, n is indicated above the corresponding bar). The proportion of vector-containing BFU-E that do not express the
transgene is significantly higher for CMV-GFP compared to the percentage observed in G-CMV-GFP-transduced BFU-E (A; P,0.005 Fisher exact test).
(B) No significant difference in the proportions of GFP
+ CFU-GM was observed between the two groups. (C–D) NOD SCID mice were transplanted with
CMV-GFP- and G-CMV-GFP-transduced CB-derived CD34
+ cells. 8–11 weeks after transplantation mice were sacrificed and BM cells were ex vivo
cultured in a medium allowing the growth of human erythroid and myeloid colonies. BFU-E and CFU-GM derived from CMV-GFP- and G-CMV-GFP-
transduced SRCs (SCID repopulating cells) were scored by PCR for vector integration. The proportion of vector-positive BFU-E that do not express the
transgene is higher for CMV-GFP vector compared to the percentage observed in G-CMV-GFP-transduced BFU-E (P,0.05; Fisher exact test). The
proportions of GFP
+ CFU-GM were similar for both vectors (P.0.1).
doi:10.1371/journal.pone.0027955.g003
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CBP occupancy at the endogenous b-globin LCR HS4 element,
chosen as an internal control, was similar in GLOBE and G-
GLOBE-transduced cells (Figure S6).
We then measured histone acetylation levels at different regions
in the GLOBE and G-GLOBE proviruses in transduced HEL
cells. Primers specific for the 59LTR and the b-globin promoter
(b-promoter-HS2) were used to amplify ChIP products by qPCR
(Figures 7A). Chromatin was immunoprecipitated using anti-
bodies against pan-acetylated H3 and specific acetylated lysines of
H3 and H4 (H3K18, H4K5 and H4K8), which are targets of CBP
activity. The G-GLOBE provirus exhibited higher H3 and H4
acetylation levels at the 59LTR compared to the GLOBE provirus
(Figure 7B). This difference is maintained at the b-globin
promoter region (Figure 7C), suggesting the spreading of
acetylated histone marks along the chromatin fiber. Histone
acetylation levels of the control, transcriptionally active Aldolase A
gene were comparable in both GLOBE- and G-GLOBE-
transduced cells (Figure S7). Concomitantly, the H3K4 trimethy-
lation (H3K4me3), typical of active promoters, tended to be higher
at the 59 LTR of G-GLOBE compared to GLOBE, whereas two
heterochromatin marks (H3K9me3 and H3K27me3) were
reduced (Figure S8A and S8B). H3K4me1, which marks
enhancer regions [41], was increased at the GATA1-HS2-
containing 59LTR (Figure S8B). Overall, these data indicate
that GATA1, together with CBP, maintains an open chromatin
structure by increasing the histone acetylation levels in the
chromatin domain delimited by the GATA1-HS2-modified LTRs.
Discussion
Gene therapy of thalassemia requires vectors expressing high,
persistent and regulated levels of b-globin. The use of b-globin
promoters, enhancers, and reduced versions of the LCR allows the
expression of potentially therapeutic levels of b-globin in the
context of LV, as demonstrated in human thalassemic erythro-
blasts in vitro [6,9] and in murine models of thalassemia in vivo
[2,5,42,43]. LV integrate in different sites in the genome, and
although they prefer open and transcribed chromatin regions [44],
their expression is susceptible to chromosomal position effects
leading to transgene silencing or variegated expression [2,8,45].
The reduced versions of the b-globin LCR are apparently
insufficient to overcome position-dependent variability of gene
expression in erythroblasts. Chromatin insulators, such as the
cHS4 element, reduce only partially positional effects, while
affecting both titer and genetic stability of the vectors [7,10,11].
The outcome of the only patient treated so far with a b-globin LV
indicates a limited contribution of the vector-derived protein in the
Figure 4. A low G-GLOBE vector copy number is sufficient to
correct of the murine thalassemic phenotype. (A) Hb concentra-
tion in peripheral blood of mice transplanted with mock-transduced
th3/+ (white column; n=8), normal (WT; black column; n=9) and
GLOBE- (GLOBE; light gray column; n=8) and G-GLOBE (G-GLOBE; dark
gray column; n=8) transduced BM th3/+ cells. Values represent the
mean and SEM for each group of animals. Hb levels were not
significantly different in th3/+ mice transplanted with GLOBE- and G-
GLOBE-transduced HSCs. (B) Percentages of Ter119
+ cells in BM of mice
transplanted with mock-transduced th3/+ (white column; n=8), normal
(WT; black column; n=9) and GLOBE- (GLOBE; light gray column; n=8)
and G-GLOBE (G-GLOBE; dark gray column; n=8) transduced BM th3/+
cells. Values represent the mean and SEM for each group of animals.
The proportion of Ter119
+ erythroid cells were not significantly different
in th3/+ mice transplanted with GLOBE- and G-GLOBE-transduced HSCs.
(C) Lack of selection of erythroid progenitors carrying multiple copies of
G-GLOBE. The Ter119
+ fraction was sorted from the non-erythroid
(Ter119
2) sub-population of BM cells from mice transplanted with
GLOBE-, G-GLOBE- and LV GFP-transduced cells and VCN was
determined by qPCR. The proportion of GLOBE-transduced cells in
the Ter119
+ fraction was 2.5 fold higher than that observed in the
Ter119
2 compartment, indicating an in vivo selective advantage of
highly transduced erythroid progenitors [5] (**P,0.01). In marked
contrast, no statistically significant difference was observed for mice
receiving G-GLOBE- and GFP-transduced BM cells (P.0.1), thus
indicating 1 copy of G-GLOBE per cell is sufficient to produce normal
Hb levels (Figure 4A). Interestingly, G GLOBE is able to rescue the
thalassemic phenotype with a significantly lower VCN compared to
GLOBE (*P,0.05).
doi:10.1371/journal.pone.0027955.g004
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transduction efficiency and genetic instability play a significant
role in this still sub-optimal vector performance.
Transcriptional enhancers can suppress negative chromatin
influences on transgene expression [21],[22], and might act more
consistently and in a larger variety of chromatin contexts compared
to conventional insulators or barrier elements. Enhancers may also
recruit a promoter to a nuclear compartment in which transcription
is stably heritable through cell generations [22]. GATA1 is a master
transcriptional activator in erythroid development, binding to
regulatory elements of most erythroid-specific genes, including the
globin enhancers and LCRs. GATA1 recruits CBP [26], which
Figure 5. Long-term human b-globin expression in the erythroid progeny of G-GLOBE-transduced HSCs. (A) SingleerythroidCFU-Swere
collected from the spleens of secondary recipients 12 days after transplantation with GLOBE- and G-GLOBE-containing BM cells (16 mice per group).
Donor cells are derived from 4 different primary recipients for each vector. LV-containing clones (40 and 24 for GLOBE and G-GLOBE, respectively)
carrying single integrants, were analyzed by FACS for b-globin expression. The percentages of b-globin
+ (light grey) and b-globin
2(dark grey) LV-
containing CFU-S are represented. Transgene expression was observed only in 25% of GLOBE-containing CFU-S, whereas the presence of GATA1-HS2
element into the LTRs was able to sustain human b-globin expression in 58% of G-GLOBE-transduced CFU-S. The difference in the proportion of
transgene expressing CFU-S between the two groups was statistically significant (P,0.005; Fisher exact test). (B) Single erythroid CFU-S were collected
from the spleens of mice 12 days after transplantation with GLOBE- and G-GLOBE-transduced BM cells (4 and 7 recipients, respectively. LV-containing
clones, carrying on average 1.6 GLOBE and 1.4 G-GLOBE integrants, respectively, were analyzed by FACS for human b-globin expression. Transgene
expressionwasobservedin83%and88%ofCFU-StransducedwithGLOBE andG-GLOBELV(n=12andn=17forGLOBEandG-GLOBE,respectively).No
statistical difference in the proportion of globin expressing CFU-S between the two groups was observed (P.0.1; Fisher exact test). (C) GLOBE and G-
GLOBE integration sites in secondary CFU-S were cloned by LM-PCR and mapped on the mouse genome. CFU-S harboring individual integration events
were analyzed for b-globin gene expression (n=11 and n=12 for GLOBE and G-GLOBE, respectively). A 2-fold increase in the proportion of b-globin
+
CFU-S carrying the G-GLOBE vector was observed compared to the percentage of GLOBE-transduced b-globin expressing colonies.
doi:10.1371/journal.pone.0027955.g005
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specific residues. The GATA1-HS2 element contains a high-affinity,
palindromic GATA1-binding element, and binds the transcription
factors CP2 [31] and BCL11A [32]. We previously showed that
GATA1-HS2 acts as an efficient, erythroid-specific enhancer in the
context of both retroviral and lentiviral vectors [33,34]. In this
study, we probed the activity of GATA1-HS2 in reducing silencing
and position-dependent variability of transgene expression in the
contextofself-inactivatingLV inwhichGATA1-HS2 was inserted in
both LTRs. The modification had no influence on the target site
selection of the vector, which maintained the typical lentiviral
preferences for active genes, enriched in H3K36me3, H4K20me1,
H3K9me1, and H3K27me1 histone modifications. Nevertheless,
GATA1-HS2-flanked transgenes showed more persistent and
position-independent expression characteristics,indicatingan active
role of the element in maintaining a permissive chromatin structure
in the target cells.
Differentiation of HSCs into erythroblasts is marked by a gradual
increase in chromatin condensation, which is associated with gene
silencing at most loci. We therefore tested whether GATA1-HS2
could prevent inactivation during erythroid differentiation of
Figure 6. GATA1 and CBP bind to GATA1-HS2-containing 59
LTRs. HEL cells were transduced with GLOBE and G-GLOBE and ChIP
assay was performed using antibodies against GATA1 and CBP. (A)
Schematic map of GLOBE and G-GLOBE vectors. Arrows indicate the
primer pairs used to amplify by PCR the viral 59 LTR. (B) Chromatin was
immunoprecipitated with antibodies against GATA1 and CBP and
isotype-matched control antibodies (Rabbit IgG). GATA1 and CBP binding
to the 59LTR of GLOBE and G-GLOBE vectors was measured by real-time
PCR. GATA1 and CBP are detected only at the GATA1-HS2-containing
59LTRs (n=2). *P,0.05 by Student t test. Error bars represent SEM.
doi:10.1371/journal.pone.0027955.g006
Figure 7. Increased CBP-mediated histone acetylation levels at
GATA1-HS2-containing LV. ChIP assay was carried out in GLOBE- and
G-GLOBE-transduced HEL cells using antibodies against pan-acetylated
histone H3, acetylated histone H3K18, acetylated histone H4K5, and
acetylated histone H4K8. (A) Map of GLOBE and G-GLOBE proviruses
Arrows indicate the primer pairs used to amplify the 59LTR and the b-
globin promoter-HS2 region. The acetylation levels are significantly
higher at the 59 LTRs (B) and at the b-globin promoter region (C) of
GATA1-HS2-containing LV compared to the GLOBE vector. (n=4).
*P,0.05; **P,0.01 by Student t test. Error bars represent SEM.
doi:10.1371/journal.pone.0027955.g007
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GATA1-HS2 in the viral LTRs effectively protects from silencing an
expression cassette driven by a silencing-prone CMV promoter in
erythroblasts differentiating from transduced murine HSCs and
human CD34
+ HPCs in vitro and in transplantation assays in vivo.
The positive effect on transgene expression was not observed in the
non-erythroblastic lineages, indicating that the presence of the
erythroid-specific GATA1 transcription factor is essential for the
activity of the GATA1-HS2 element. GATA1 is expressed also in
megakaryocytes, eosinophils, and mast cells, which cannot be
detected at high frequency in fresh BM cells. In vitro cell culture
experiments will be necessary to unravel the potential GATA1-HS2
anti-silencing effect in these lineages.
We then tested the activity of GATA1-HS2 in the LTRs of the
GLOBE LV, containing a human b-globin gene under the control
of its promoter and a minimal version (HS2+HS3) of the b-globin
LCR [5]. The GLOBE vector is able to correct thalassemia in a
murine pre-clinical model of gene therapy [5] and in the
erythroblastic progeny of human thalassemic HPCs [6]. The
therapeutic efficacy is achieved even at low dose of transduced
HSCs by in vivo selection of transgene-expressing erythroblastic
cells, possibly overcoming the negative influence of chromatin
surrounding the LV proviruses. We observed that silencing of the
b-globin transgene in the erythroid progeny of human HPCs and
murine HSCs transduced with the G-GLOBE vector was
significantly reduced compared to cells transduced with the
GLOBE vector. As a consequence, the G-GLOBE vector allowed
correction of murine thalassemia at a lower copy number and
without inducing the in vivo selection observed with the GLOBE
vector [5]. Therefore, reducing position-dependent variability of
gene expression increases the vector’s therapeutic potential,
providing disease correction at lower vector copy number.
Remarkably, the LTR modification does not impair the viral
titer, probably because of the limited size of the GATA1-HS2
(2.0610
9 vs. 1.4610
9 TU/ml for a typical preparation of GLOBE
and G-GLOBE, respectively).
The major difference between the two vectors was observed in
the progeny of long-term repopulating HSCs, assayed as CFU-S in
secondarily transplanted mice, indicating that the GATA1-HS2
provides a more effective long-term protection from silencing
compared to to the LCR alone. However, position effect
variegation, resulting in expression or silencing in different
colonies from CFU-S harboring the same provirus, was observed
for both vectors, indicating that GATA1-HS2 increases the
probability of expression but is unable to completely prevent
silencing in the long-term progeny of transduced HSCs.
In order to understand the molecular basis of the protective
effect of GATA1-HS2, we carried out ChIP studies on erythro-
blastic cells transduced with the GLOBE or G-GLOBE vectors. A
typical function of enhancers is to prevent the formation of
repressive chromatin structure by controlling histone acetylation
and methylation around promoters. Binding of GATA1 to
erythroid-specific enhancers during development or differentiation
is a key factor in the initiation and maintenance of active
chromatin structures [46]. The interaction of GATA1 with CBP/
p300 suggests at least one mechanism by which HATs might be
brought to specific sites [26],[47]. By modifying chromatin-bound
histones or GATA1 itself [28], acetylases enhance transcriptional
activity of erythroid-specific loci [27]. In this context, GATA1 is
more an ‘‘architectural’’ factor than a simple transcriptional
activator. The essential role of GATA1 and CBP for the formation
of an erythroid-specific acetylation pattern that is permissive for
high levels of gene expression has been reported at the LCR and
the murine ß-major globin gene promoter [40,48]. Our study
shows that binding of GATA1 and CBP to the GATA1-HS2
element correlates with increased CBP-mediated histone acetyla-
tion (H3K18, H4K5, and H4K8) at the level of the LTRs and the
internal promoter. Although GATA1 and CBP bind also the LCR
elements and the b-globin promoter within the vector, the
presence of the GATA1-HS2 element at both sides of the transgene
apparently increases CBP-mediated histone acetylation and
spreads the acetylated histone domain to a chromatin region that
encompasses the entire provirus. This might create a more stable,
inheritable active chromatin configuration that renders the
integrated transgene resistant to silencing in a large proportion
of integration sites.
Our results suggest that GATA1 establishes an active epigenetic
state across transgenes flanked by GATA1-HS2 elements in the
context of LV. Therefore, this vector design represents a way to
shield integrated transgenes from negative chromosomal position
effects, improving the therapeutic potential of LV-mediated gene
therapy approaches. Further studies addressing the impact of this
lineage-specific enhancer on cellular transcriptional activity are
necessary to assess the risk-benefit balance for potential clinical use.
Materials and Methods
Lentiviral vectors
The CMV-GFP lentiviral vector was previously described [35].
To construct the G-CMV-GFP vector, an EcoRI/SacI fragment
containing part of the 39 LTR of the lentiviral vector pHR2 [49]
was subcloned into the PvuII site of the pUC19 plasmid. The
plasmid was digested with EcoRV and PvuII, in order to generate a
2418 to 218 deletion (where +1 is the transcription start site) in
the U3 region of the LTR, and ligated with a 200-bp BamH1
human genomic fragment (2856 to 2655) containing the GATA1-
HS2 [24] to obtain a chimerical self inactivating (SIN) LTR. The
EcoRI-SfiI fragment containing the modified 39 LTR was then
introduced into the EcoRI-SfiI sites of the CMV-GFP backbone
[50], to obtain the G-CMV-GFP vector. To generate the G-
GLOBE vector, the EcoRI-SfiI HS2 SIN LTR fragment was
introduced into the SpeI-SfiI sites of the GLOBE vector backbone.
Viral vector stocks were prepared by transient co-transfection of
HEK293T cells using a three-plasmid system as previously
described [5]. HEK293T cells were kindly provided by Luigi
Naldini.
Transduction of stable cell lines
HEL (human erythroleukemia) cell line was grown in RPMI
1640 supplemented with 10% FBS, 100 U/ml penicillin/strepto-
mycin and 2 mM L-glutamine, and transduced with viral stocks at
a multiplicity of infection (MOI) of 20 in the presence of 8 mg/ml
polybrene. HEL cells were purchased by ECACC (European
Collection of Cell Cultures).
Transduction and transplantation of murine HSCs and
human HPCs
BM cells were harvested from C57BL/6-Ly-5.1 mice (B/6.SJL-
CD45
a-Pep
3b, Jackson Laboratories), infected with CMV-GFP
and G-CMV-GFP vectors, and injected into 8-wk-old C57BL/6
mice (Charles River) as previously described [33]. BM cells from
C57BL/6-Hbb
th3 mice (Jackson Laboratories), were infected and
transplanted into 8-wk-old C57BL/6-Ly-5.1 and C57BL/6-
Hbb
th3 mice, as previously described [5]. C57BL/6 or C57BL/
6-Ly-5.1 mice were lethally irradiated (950 cGy) and secondarily
transplanted with 10
5 total BM cells from primary transplanted
animals. Spleen colony-forming units (CFU-S) were isolated at day
12 from the spleen of 8- to 12-wk-old secondarily transplanted
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+ cells were obtained from umbilical cord
blood of healthy donors on collection with written informed
consent in accordance with the Declaration of Helsinki (TIGET01
protocol). This study was approved by San Raffaele Scientific
Institute Ethical Committee. CD34
+ cells were cultured, trans-
duced and transplanted (2.5610
5 cells/mouse) in NOD-SCID
mice (Charles River) as previously described [33]. All procedures
were approved by the H. San Raffaele Animal Care and Use
Committee (IACUC#295).
Hematological and cell phenotype analysis
Blood samples were collected from transplanted mice and Hb
concentration, hematocrit, RBC and reticulocyte counts were
measured as described [5]. RBC and CFU-S were stained with
PE-conjugated anti-human b-globin antibody as described [5,51].
Mouse BM and spleen cell phenotyping was carried out using PE-
conjugated anti-mouse TER-119 antibody. PE-conjugated anti-
mouse CD45.1 and PerCP-conjugated anti-mouse CD45.2
antibodies were used to evaluate donor-host chimerism. Human
cell surface phenotype and human cell engraftment in transplanted
NOD/SCID mice were determined as described [33]. Unbound
antibodies were removed by a final wash with PBS 1% FBS and
cells were analyzed using a FACScalibur cytofluorimeter (Becton
Dickinson, Mountain View, CA). Ter119
+ BM cells were purified
as previously described [5]. Antibodies are listed in the
Supplemental Materials and Methods (Text S1).
DNA analysis
Genomic DNA was isolated with the QIAGEN QIAmp DNA
mini kit. GFP-specific primers were used to detect the presence of
CMV-GFP and G-CMV-GFP vectors. Primers that anneal to the
human HS2-HS3 LCR sequence were used to detect GLOBE and
G-GLOBE vectors. Primer sequences are listed in Supplemental
Materials and Methods (Text S1). The average vector copy number
(VCN) was measured by qPCR as previously described [5].
Integration site analysis
Integration sites were cloned by linker-mediated PCR (LM-PCR)
as previously described [38]. Briefly, genomic DNA was extracted
from human HPCs, murine BM cells or CFU-S, digested with MseI
and ligated to an MseI double-stranded linker. LM-PCR was
performedwith nestedprimersspecific forthelinkerandthe39HIV
LTR [38]. PCR products were shotgun-cloned into libraries of
integration junctions, which were then sequenced to saturation.
Sequences were mapped on the human (UCSC Human Genome
Project Working Draft, hg18) or mouse genome (UCSC Mouse
Genome Project Working Draft, mm9) by the BLAT genome
browser. A matched random integration dataset was created for the
human genome as described [38]. We annotated all genes having
their transcription start site (TSS) within 50 kb from each
integration/random site in either directions. Integrations were
annotated as TSS-proximal when occurring within 62.5 kb from a
TSS, intragenic when occurring inside a gene .2.5 kb from a TSS,
and intergenic in all other cases. In case of multiple transcript
variants, we chose the longest isoform.
ChIP assay
ChIP assay was performed as described [44]. Samples were
quantified using real-time SYBR Green PCR and analyzed using
an Applied Biosystems 7900HT system. Serial dilution of total
input chromatin was used to generate a standard curve for each
primer and sample set. Primers sequences and antibodies are listed
in Supplemental Materials and Methods (Text S1).
Statistical analysis
We used a 2-tailed Student’s t test to determine whether
hematological parameters, fractions of inputs and VCN differed
between groups. Fisher’s exact test was used to assess whether the
difference between two proportions was significant. The statistical
analyses were performed using GraphPad Prism Version 4.0b
(GraphPad Software Inc., La Jolla, CA).
Supporting Information
Figure S1 Increased transgene expression in the Ter119
+
compartment of mice receiving G-CMV-GFP-transduced
HSCs. GFP expression was analyzed by FACS in the erythroid
Ter119
+ fraction of BM from mice transplanted with CMV-GFP-
and G-CMV-GFP-transduced HSCs, as described in the legend to
Figure 2. Both MFI and percentage of GFP
+ cells are significantly
higher in mice receiving G-CMV-GFP-transduced cells (*P,0.05;
****P,0.001; n=9 for CMV-GFP and n=8 for G-CMV-GFP).
(EPS)
Figure S2 Similar correction of haematological param-
eters in mice transplanted with GLOBE- and G-GLOBE-
transduced BM. RBC count, HCT and percentages of
reticulocytes, in peripheral blood of mice transplanted with
mock-transduced th3/+ (white column; n=8), normal (WT; black
column; n=9) and GLOBE- (GLOBE; light gray column; n=8)
and G-GLOBE (G-GLOBE; dark gray column; n=8) transduced
BM th3/+ cells. Values represent the mean and SEM for each
group of animals. Haematological parameters were not signifi-
cantly different in th3/+ mice transplanted with GLOBE- and G-
GLOBE-transduced HSCs.
(EPS)
Figure S3 The presence of HS2 does not affect the
lentiviral integration pattern in human CD34
+ hemato-
poietic progenitors. (A) Distribution of CMV-GFP and G-
CMV-GFP integration sites in the genome of cord blood-derived
CD34
+ cells. Integrations are defined as intergenic (outside genes),
intragenic (inside genes) and TSS-proximal (at a distance of
62.5 kb from transcriptional start sites, TSSs) as described in the
scheme. No statistical differences between the two groups were
observed. (B) Distribution of LV integrations sites in human CD34
+
cells within an interval of 50 kb around the TSSs of known genes.
Thebarsshowthe percentage ofdistributionineach5-kbinterval of
CMV-GFP and G-CMV-GFP insertions. The red line shows the
distribution of computer-generated random insertion sites.
(EPS)
Figure S4 Correlation between CMV-GFP and G-CMV-
GFP integration sites and gene activity. The bars show the
percentage of distribution of expression values from Affymetrix
HG-U133A microarrays of CD34
+ cells at the time of transduc-
tion. Target genes are divided in four expression level categories:
absent (black), low (below the 25
th percentile in a normalized
distribution; blue), intermediate (between the 25th and the 75th
percentiles; yellow) and high (above the 75th percentile; red). The
first bar (Chip CD34
+) shows the distribution of the genes on the
microarray of CD34
+ cells at the time of transduction, the other
three bars represent the expression values of genes at control
random sites (Random) or genes targeted by CMV-GFP and G-
CMV-GFP integrations. n represents the number of genes.
(EPS)
Figure S5 Association between histone modifications
and CMV-GFP and G-CMV-GFP integrations sites. Total
number of base pairs carrying the indicated histone modification/
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(green), G-CMV-GFP (blue) and random (grey box) insertion site.
The distributions of the entire datasets are represented by box
plots. Data were retrieved from ChIP-sequencing experiments
performed in the genome of human CD34+/CD133+ HPCs [39].
Two-sample test statistics among CMV-GFP, G-CMV-GFP and
random distributions for each modification indicate that compar-
isons between CMV-GFP and G-CMV-GFP are not statistically
significant (non parametric Mann–Whitney U test, not shown). All
comparisons between LV and random distributions are statistically
significant (*P,0.05; ****P,0.001; Random: n=9974; CMV-
GFP: n=438; G-CMV-GFP: n=305).
(EPS)
Figure S6 GATA1 and CBP occupancy at the endogenous
LCR HS4. Chromatin from GLOBE- and G-GLOBE-trans-
duced HEL was immunoprecipitated with antibodies against
GATA1 and CBP and control rabbit IgG. The endogenous LCR
HS4 served as a positive control for GATA1 and CBP binding in
both GLOBE- and G-GLOBE-transduced bulk populations
(n=2). Error bars represent SEM.
(EPS)
Figure S7 Similar acetylation levels at the control
AldolaseA gene. ChIP assay was performed as described in
the legend to Figure 7. The levels of histone H3 and H4
acetylation are comparable at the positive control region from
Aldolase A gene in both GLOBE- and G-GLOBE-transduced
HEL cells (n=4). The results are averages of 4 independent
experiments. Error bars represent SEM.
(EPS)
Figure S8 Analysis of histone methylation patterns at
the 59LTR and at the b-globin promoter-HS2 region of
GLOBE and G-GLOBE vectors. ChIP assay was carried out in
GLOBE- and G-GLOBE-transduced HEL cells using antibodies
against mono- and trimethyl-H3K4 (H3K4me1 and H3K4me3)
and against trimethyl-H3K9 and trimethyl-H3K27. qPCR was
performed to amplify the 59LTR (A) and the b-globin promoter-
HS2 region (B). Bars denote averages of 4 independent
experiments. Error bars represent SEM.
(EPS)
Table S1 VCN and number of integrants in primary trans-
planted mice used as donors for CFU-S assays. The table shows
the number of integration sites retrieved from BM of primary
transplanted mice, the average vector copy number per BM cell,
and the number of CFU-S analyzed for each primary transplanted
mouse.
(DOC)
Table S2 Human b-globin expression in mice transplanted with
GLOBE- and G GLOBE-transduced BM. The table shows the
percentage of human ß-globin positive RBC and the ratio between
the areas of HPLC peaks corresponding to human ß and murine a
globin chains in mice transplanted with GLOBE- and G GLOBE-
transduced BM.
(DOC)
Table S3 List of GLOBE proviral integration sites in secondary
CFU-S. The table shows b-globin expression, chromosomal
location of integrated provirus, target gene symbol, and RefSeq
identifier number in secondary CFU-S. Integrations were
annotated as inside or outside (intergenic) known genes (University
of California at Santa Cruz annotation).
(DOC)
Table S4 List of G-GLOBE proviral integration sites in
secondary CFU-S. The table shows b-globin expression, chromo-
somal location of integrated provirus, target gene symbol, and
RefSeq identifier number in secondary CFU-S. Integrations were
annotated as inside or outside (intergenic) known genes (University
of California at Santa Cruz annotation).
(DOC)
Text S1 Additional Materials and Methods.
(DOC)
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